Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 3 Recruiting 412 enrolled Chengdu CoenBiotech Co., Ltd Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A phase III multi-center randomized, double-blind and positive-controlled clinical trial for evaluating the efficacy and safety of BCG for Therapeutic Use（BCG） in the prevention of postoperative recurrence of medium/high-risk non-muscle invasive bladder cancer (NMIBC).

Timeline

Start: 2023-12-28
Primary completion: 2025-09-01
Completion: 2026-09-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BCG	Unknown	120 mg	Other

Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Summary

Timeline

Drugs

Indications